Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There will be a nice bounce coming.
The r/split has caused an interesting situation:
-drop the share count to a ridiculous low number, around 5 Million shares, creates a set up for one hell of a jump on PR if the market likes it.
-BUT if they need cash, I suspect the next move will be for a secondary, ATM of something like at least 10-15 Million shares to raise cash
-the higher share price will make it possible for the institutionals to be interested in the shares. Said it before, we the 'little people' aren't going
to pull the share price up by our own actions, it requires the institutionals. (was hoping to see 50 cents before they did a r/split tho)
-and I am now wondering if they know WHEN and WHAT the PH 3 results are?? Or at least know that its going to be available for release and that
it will negate the effect of the r/split and prevent at least in the short term, the piling on of the short sellers..
This has gotten ugly and interesting. On one hand, I missed out on the hit last night, so I can at least observe.
Remember, the biggest thing in this market is, is their MARKET CAP unreasonable relative to the potential revenues. I use that as a guide
to whether or not I want the shares at the PRICE & SHARE COUNT its at.. Is their justification for a higher share price.. To be determined.
DISCLAIMER: At the moment, I have no idea what a REASONABLE MARKET CAP is for them. I was only trading the shares for what I could
get while trying to figure this out. Good luck. Own none at the moment. Undecided as to whether or not I will again.
Honestly from what I've been watching I would be extremely careful on Monday. Remember the international markets were all closed, but everyone has seen this dip and I'm sure A LOT of people are pissed the fuck off. The Frankfurt market still has a share price of .24 EU , there is going to be a massive correction and sell off before anything else happens. The one thing I don't understand is why put out PR after hours and leave only the US market open to get dumped. Something is definitely happening behind the scenes. Stay safe y'all, I feel bad for everyone who watched their portfolio take an instant -50% L , including my own.
ouch...they worked the sheeep here once again
I don’t think they will have to cover the shorts.
If anything they will short more on the 23rd.
The split new price could be about $8 a share.
The shorts will hit it again to try to get it below $2
Then they may think about covering
There should be about 4.88 million shares after the split.
That is about the amount of shares when i 1st bought shares maybe 7 million shares.
JAGX kept selling shares into the market diluting shares. They will do it all over again if history repeats.
If they do a RS won’t it shake out all the short positions after the split and with phase 3 PR should pop huge!!!! Especially with all the craze hot meme stocks???
FFIE saved the day…
How do you think it will fare next week, before the split? Drop some more? More selling, more buying? The r/s 1:60 is horrible for any stock, but this has a big catalyst coming. Honestly, i don't know what to do on monday.
This management team at JAGX has hurt alot of investors through the years
I just sold my last 10,000 shares @ .14 that i paid 67 cents for but because i loaded way up around 10 cents that i made a profit on JAGX to the point that these were free trading shares.
If there is one thing i do not like it is the brutal reverse split.
This stock is brutal to the shareholders
I wish everyone the best of luck here.
I know how you feel...been burned like that enough... but at least they have a big hopeful catalyst ahead...many times a company has absolutely nothing in the works when they split....but not the case with JAGX...I hope it ends well for all involved.
Oh, i'm sure that's the plan, i mean, there's no other explanation for it. It's just a massive headache atm...
You never know DanDosh they might just do that directly after the split...it might be a strategic move so institutions might take interest.
but the only saving will still be those damn PIII results
At least it's a nice price to buy right now, for those that still have $ left aside to gamble the PIII catalyst. I think it will bounce a bit back, till may 23, based on this logic. Right?! Or maybe it's just my stupid copium, that got me burned so many times. God dammit...
They want to make it attractive to investors.... They'll announce PIII results, positive, at ASCO, but first they needed a stock with a price that's more attractive. It's a shitty situation, i had hoped they wouldn't do this, but they did nonetheless.
I figured they would at least wait until July considering they had until August 13th 2024.
I'm so pissed right now to sell at loss this pos stock, but the only saving will still be those damn PIII results. FFS. I should have listened when people said this stock murders its stockholders...
Split won't happen until next Thursday May 23rd
Yeah they announced it on their website before filing it.
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-inc-announces-reverse-stock-split
Apparently, your dream turned into a nightmare.
Not finding that announcement on EDGAR or OTC markets...can you post the link?
Well now, thats a pretty frigging ugly to do on a Friday night..
Hope the next thing they say is the PH 3 results to help absorb the blow from the r/split or this will be a short seller target..
What the Sam hell fuck happened ???!!!!
RS 1:60 announced
did the PH 3 fail?? or is this a FRIDAY headfake??
what in the heck is happening??? 14 cents
I agree the longer the consolidation, the better, but here it's a matter of days ("imminent", whatever it means in the CEO's head), or two weeks max, till may 31-june 4 (asco). Anything beyond that and no one will hold this anymore. Even for two weeks, i would be surprised if it holds current levels, without any external input... Problem with waiting is you don't really know when they'll drop the big news, and you'll be left out. If they didn't used the term "imminent", i too think i would have waited a bit more, closer to ASCO. But i bought at 0.27 and let it sit, i've been burned before trying to time such things...
I'm using the 3rd when it peaked and lower highs started. So its in day 11 of the 'consolidating' its gains..
But for a 'good' consolidation? I expect to see 5 weeks min to shake folks out.. and I expect to see some
heavier volume days indicating those considering selling, threw in the proverbial towel and the flush out is over.
Does it mean its going to happen like that with this one? Will only know once its 'over' and the next leg up commences.
Heck it may hold at 26 cents +.. TBD'd..
disclaimer: own none, and don't like the activity today enough to take a run at a trade.
But will own some hopefully before the 'imminent' PR occurrs. just to see what happens.
And yes, would like to see from a 'selfish' standpoint, 21-23. And for those not selling, just holding, it won't matter what it does till the PR
is released.. cause the expectation is for higher.. when its said and done
Personally, i think it's been consolidating since 7th of May, between .25 and .3, much of it between .26 and .28. If it drops below 0.25, to the 0.21 - 0.23 range, i would start to worry... it would suck. But i've seen the stock reaction when it dropped briefly (twice) to ~0.24, it got immediately bought up, so i'm not too worried in the short term.
No idea how deep it MIGHT drop, or if it even will. Heck, it might just run flat here at 26-27. But after these kinds of runs, some CONSOLIDATION is NEEDED to set a new base price...
But after this much momentum to get to this price level?? and the expectation of 'more'??
TBD'd what happens between now and the next 'imminent' PR..
no big drop buy when scared
There won't be a big drop soon, without bad news, just like there won't be a big run up without good news. It's just consolidation and trading. It won't drop much because there's demand in anticipation of PIII results. Zoom out the chart, if you feel unsure, you'll see.
That’s how I feel. Afraid from big drop soon
Who knows it’s 50/50 worth the gambling$$$ Thank you!
Thank you so much! And good luck$$$
we are currently 367% off the lows in February, almost the time people bailed on the stock. We had a huge 255% move off the bottom in a few days, I wonder if we can get a 500-1000% move off news 🥰
.64c then $1.15 then $3.05, then moon
Sold yesterday at 28.27... chart is showing some 'caution' signs. Its ran hard, is overdue for a good shake out, and
after the nice run it made, going to be interesting to see if the longer it 'sits' flat if holders start to get impatient and start locking in
their gains. Especially IF it starts to show thats happening and it becomes self feeding into a pullback.
A friend and I have been trading shares the last few days in a take what it gives approach. He has gotten
a bit enthusiastic expecting the buy low sell high is going to keep working out. And it might if he takes what it gives
vs 'seeing' how much he can get by just holding out for a little more.
But my primary momentum indicator has gone negative, and another one is flashing a warning that
it too could turn negative. But thats to be expected in a CONSOLIDATION phase.
Too early to tell if thats whats going on, but if it does get a foothold, going to be interesting
to see what the share price does (run flat, pullback some TBD'd)
Disclaimer: own none, traded shares 2x now after the big run up.. Looking to try again today..
But being patient not to trap myself..
So AMC THEN FFIE if it’s going alphabetical order we should be up next lol
forthcoming adjective (SOON)
happening soon: We have just received the information about the forthcoming conference.
Can’t wait till this is a UPDATED PR!!!!
Jaguar Health (JAGX) Reports Majority of Subjects in Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
December 11, 2023 8:32 AM
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar) family company, today announced that a majority of subjects in the company's placebo-controlled pivotal Phase 3 OnTarget trial for prophylaxis (prevention) of diarrhea in adult cancer patients receiving targeted therapy with or without standard chemotherapy chose to continue on to Stage II of the two-stage trial.
After completing the Stage I double-blind, placebo-controlled primary prophylactic treatment phase of OnTarget, subjects had the option to remain on their blinded assigned treatment arm and reconsent to enter into the Stage II extension phase.
"We are very pleased that a majority of subjects chose to continue on to Stage II while recognizing that their requirement to remain blinded would continue," said Lisa Conte, Jaguar's president and CEO. "We are deeply committed to all patients who participated in the OnTarget trial. We view them as key stakeholders and we thank them for their support and participation in this study."
Stage II of the trial has concluded. Inclusion of Stage I data and Stage II data, with success, is required in the supplemental NDA filing of crofelemer to add the indication for prophylaxis of diarrhea in cancer patients receiving targeted therapy with or without standard chemotherapy.
"Since all patient data will be included in the final locked database, we will remain blinded and will announce the comprehensive results of the full trial, including Stage II results, rather than proceeding with the original plan of announcing top line results for Stage I only. We expect the full trial results to be available in the first quarter of 2024," Conte said. "The clinical trial database includes patients with multiple solid tumor types, and the trial allowed the inclusion of 24 different targeted therapies, including multiple important mechanisms of action for targeted therapy drugs."
OnTarget is a first-of-its-kind, 24-week (two 12-week stages) clinical trial with a primary endpoint based on patient-reported outcomes that address the highly neglected and unmet burden of cancer therapy-related diarrhea, an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic and/or episodic debilitating diarrhea (loose and/or watery stools), urgency, bowel incontinence and abdominal pain and discomfort.
Diarrhea is a common side effect of targeted therapies and new treatments are needed. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.1 The OnTarget study is testing whether the company's plant-based prescription drug crofelemer (versus placebo) can prevent (or substantially reduce) diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies (that are associated with diarrhea in at least 50% of patients) is initiated.
"We are excited as any stakeholder to see the results. We own the expectation we set that data would be available in November 2023. We have to respect and abide by the requirements and Standard Operating Procedures of our third-party service providers and work with them as we meet GCP (Good Clinical Practice) requirements, particularly when conducting a complex global Phase 3 clinical trial," Conte said. "These service providers have important quality control procedures that take time and somewhat expand as the data analysis process progresses. We are working with all vendors that are critical to ensure the integrity of the data. Jaguar and Napo personnel continue to remain blinded to the study results at this time."
Napo's abstract outlining the design of the OnTarget trial, the importance of patient reported outcomes, and the neglected medical need of CIOB was the subject of a poster presentation on December 7, 2023 at the San Antonio Breast Cancer Symposium (SABCS). More than two dozen leading patient advocacy groups provided powerful voices at events hosted by Napo, highlighting the neglected need of mitigating diarrhea in patients receiving cancer therapies, and expressing strong support for the company's focus on patient quality of life.
$1.00+ will come. Management has faith in P3. P2 was great, already approved for animals we are looking very good.
If all the “penny stocks” are going MOASS with no new news and just speculative plays but WE ARE FIGHTING CANCER THAT $1 should be attainable and waaaay more. Just saying…
Even the AI who smarter than me atleast agrees it will go to a $1 soon
https://coincodex.com/stock/JAGX/price-prediction/
But first.... .40 today.😁
The at 5 day BULL FLAG LOOKONG GOOD ONLY TIME NOW TOLL WE POP!
Followers
|
137
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6957
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Pipeline: https://jaguar.health/pipeline/
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |